Following up on bfw's previous message, anyone else notice that Zenith has removed almost all mention of autoimmune indications from their website? When the RVX/Zenith split initially happened, the split of compounds was dictated by whether compound 1, 2, 3 modulated apoAI gene transcription by X amount. If it did, it belonged to RVX. If it didn't, it belonged to Zenith. Now that the apoAI modulating effect of RVX-208 have been downplayed in favor of the multi-modal effects of BET bromodomain inhibition, what currently defines the split of compounds? I believe in the past DM said that RVX has like 1500 compounds and Zenith 2500. Are all of these BET inhibitors? Do both companies have BD1 vs. BD2 selective BET inhibitors? Is only one company going after autoimmune conditions? Is only one company going after other inflammation conditions? Is only one company going after oncology indications? Is only one company going after complement-mediated diseases? Is only one company going after cardiovascular and renal? Since both companies are CEO'd by DM, it would be nice to get an update on how the IP, disease indications, and MOA are differentiated between the two companies.

BearDownAZ